BSD Medical Reports Impressive Results from Clinical Study on Pancreatic Cancer Presented at ESHO 2010 Meeting

SALT LAKE CITY--(BUSINESS WIRE)-- BSD Medical Corporation (NASDAQ: BSDM) today reported impressive results from a clinical study on the use of hyperthermia, delivered using the BSD-2000 Hyperthermia System, to treat pancreatic cancer. Dr. S. Maluta, University Hospital of Verona, Italy, reported the results of a randomized Phase II study of 74 patients with advanced pancreatic cancer: “Hyperthermia combined with radiochemotherapy in unresectable locally or recurrent advanced pancreatic cancer, a Phase II perspective study.”

Dr. Maluta reported that the recurrent and metastatic pancreatic patients who were treated with hyperthermia combined with radiochemotherapy had a median survival of 14 months, as compared to a median survival of only 5 months for those treated with radiochemotherapy alone (n=20). The one-year survival was increased by 3 months for all patients who were treated with hyperthermia, as compared to patients who did not receive hyperthermia treatment (n=54). The treatment was well tolerated with no increase in toxicity from the addition of hyperthermia. Dr. Maluta reported that these results support initiation of a Phase III study. The results were presented at the annual European Society for Hyperthermic Oncology (ESHO) Meeting, which was held in Rotterdam, The Netherlands, on May 19 to 21, 2010.

Rolf Issels MD PhD, the President of ESHO, supported initiation of a randomized Phase III study on hyperthermia treatment of pancreatic cancer and stated in his keynote lecture, “In a time of evidence based oncology loco-regional hyperthermia has proven its value and deserves a greater focus and exploration.”

Pancreatic cancer is one of the deadliest and hardest to treat cancers and is the fourth leading cause of cancer-related death in the United States. More than 30,000 people in the US and 60,000 in Europe are annually diagnosed with pancreatic cancer. The median survival period from the time of diagnosis until death is 3.5 to 6 months, depending on treatment, and less than 5 percent survive to five years. Advanced pancreatic cancer patients currently have few treatment options.

About the European Society for Hyperthermic Oncology

ESHO was organized to promote research relating to the use of hyperthermia in cancer therapy and to facilitate the exchange of information among multiple disciplines regarding the study of heat in the treatment of cancer.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radio frequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system, which the Company will introduce to the market this year, has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has extensive intellectual property, multiple products in the market and well established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. The BSD-2000 is restricted to investigational use in the US. For further information visit BSD Medical's website at www.BSDMedical.com.

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.



CONTACT:

BSD Medical Corporation, Salt Lake City
Dennis Gauger, 801-972-5555
Fax: 801-972-5930
[email protected]

KEYWORDS:   United States  Europe  North America  Netherlands  Utah

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Hospitals  Medical Devices  Oncology  Radiology  Other Health  FDA

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.